A survey among hospital specialists and pharmacists about biosimilars

European Journal of Internal Medicine

Volumn 35, Issue , 2016, Pages e31-e33

  Pasina, Luca ^a   Casadei, Gianluigi ^a   Nobili, Alessandro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Biological agents; Biosimilars; Drug information; Regulatory

Indexed keywords

BIOSIMILAR AGENT; FILGRASTIM; HUMAN GROWTH HORMONE; INFLIXIMAB; RECOMBINANT ERYTHROPOIETIN;

CARDIOLOGIST; DERMATOLOGIST; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; EDUCATION; EDUCATIONAL INTERVENTION; ENDOCRINOLOGIST; GASTROENTEROLOGIST; HEMATOLOGIST; HUMAN; IMMUNOGENICITY; INTERNIST; LETTER; LICENSING; MEDICAL SPECIALIST; NEPHROLOGIST; ONCOLOGIST; PEDIATRICIAN; PHARMACIST; PREJUDICE; PROFESSIONAL KNOWLEDGE; RHEUMATOLOGY; ATTITUDE TO HEALTH; CLINICAL TRIAL; DRUG APPROVAL; ECONOMICS; GERMANY; HEALTH PERSONNEL ATTITUDE; MULTICENTER STUDY; QUESTIONNAIRE; SPECIALIZATION; STANDARDS;

ATTITUDE OF HEALTH PERSONNEL; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; GERMANY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHARMACISTS; SPECIALIZATION; SURVEYS AND QUESTIONNAIRES;

EID: 84997531378     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2016.07.010     Document Type: Letter

References (10)

1. [1] Mellstedt, H., Clinical considerations for biosimilar antibodies. EJC Suppl 11:3 (2013 Dec), 1–11.
2. [2] GaBI online — use of biosimilars in Europe differs across countries. Available from: http://gabi-journal.net/news/use-of-biosimilars-in-europe-differs-across-countries.
3. [3] European Medicines Agency, Scientific guidelines on biosimilar medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c#Productspecificbiosimilarguidelines [Accessed on May, 2016].
4. [4] Fiorino, G., Girolomoni, G., Lapadula, G., et al. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 13:7 (2014 Jul), 751–755.
5. [5] Thill, M., New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. Expert Rev Anticancer Ther 15:3 (2015 Mar), 331–338.
6. [6] Fodmark, C.E., Lilja, K., Woehling, H., et al. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther 3 (2013), 35–43.
7. [7] Romer, T., Zabransky, M., Walczak, M., et al. Effect of switching recombinant human growth hormone: comparative analysis of phase 3 clinical data. Biol Ther, 1, 2011 Dec 16, 5.
8. [8] Finnish Medicines Agency, Are biosimilars interchangeable?. https://www.fimea.fi/web/en/-/are-biosimilars-interchangeable- [Accessed on May 20, 2016].
9. [9] Park, W., Yoo, D.H., Miranda, P., et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis, 2016 Apr 26 [pii: annrheumdis-2015-208783].
10. [10] Yoo, D.H., Prodanovic, N., Jaworski, J., et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis, 29, 2016 [pii: annrheumdis-2015-208786].